{"id":209,"date":"2018-10-26T23:14:59","date_gmt":"2018-10-27T06:14:59","guid":{"rendered":"https:\/\/derm-biomepharmaceuticals.com\/?p=209"},"modified":"2019-01-23T23:54:24","modified_gmt":"2019-01-24T07:54:24","slug":"derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets","status":"publish","type":"post","link":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/","title":{"rendered":"Derm-Biome Pharmaceuticals Inc. beginnt mit der Erprobung seiner propriet\u00e4ren Verbindungen an Hautmikrobiom-Zielen."},"content":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]<\/p>\n

26. Oktober 2018<\/h4>\n

VANCOUVER, British Columbia \u2013 Das in Vancouver ans\u00e4ssige Mikrobiom-Startup Derm-Biome Pharmaceuticals Inc. freut sich, bekannt zu geben, dass es das Centre for Drug Research and Development (CDRD) damit beauftragt hat, mit der Erprobung seiner patentierten Verbindungen an verschiedenen Krankheitserregern zu beginnen. Die Leitsubstanz DB-207 zeigt ein erhebliches Potenzial bei Patienten mit Akne, Rosacea, leichten bakteriellen Hautinfektionen, Konjunktivitis und neoplastischen Hauterkrankungen, mit dem positiven Nebeneffekt, dass sie das Erscheinungsbild der umgebenden Haut verbessert. Der preisgekr\u00f6nte Forscher Dr. Poul Sorensen und sein Labor am BC Cancer Research Center werden bald damit beginnen, DB-207 auf seine Wirkung auf Entz\u00fcndungen und Hautkrebs zu testen. Der Fokus des Unternehmens liegt zun\u00e4chst auf den Bereichen Kosmetika (Anti-Aging-Produkte) sowie entz\u00fcndliche und neoplastische Hauterkrankungen, die beide gro\u00dfe Marktchancen bieten.<\/p>\n

\u00dcber Derm-Biome Pharmaceuticals, Inc<\/h4>\n

Derm-Biome Pharmaceuticals Inc. ist ein neu gegr\u00fcndetes Life-Science-Unternehmen mit erteilten Patenten f\u00fcr \u00fcber vierzig optimierte Naturstoffe, das sich in das neue und spannende Gebiet des Hautmikrobioms vorwagt. Das Unternehmen ist begeistert, dass seine Verbindungen in der Lage sind, unsere eigenen einzigartigen Bakteriengemeinschaften auszugleichen und ihnen Diversit\u00e4t zu verleihen. Eine stabile Umgebung kann sich positiv auf die Gesundheit unserer Haut auswirken, das Aussehen verbessern und Krankheiten, einschlie\u00dflich Hautkrebs, abwehren. Dar\u00fcber hinaus haben diese Verbindungen direkte Auswirkungen auf das Zellwachstum und das \u00dcberleben, die derzeit vom Unternehmen untersucht werden.<\/p>\n

Kontakte<\/h4>\n

Derm-Biome Pharmaceuticals, Inc.<\/strong>
\nInvestorenanfragen:
\nGord Eberwein
\ngeberwein@derm-biome.com[\/vc_column_text][vc_separator type=”normal” color=”#cccccc” thickness=”1″ up=”50″ down=”50″][\/vc_column][\/vc_row]<\/p>","protected":false},"excerpt":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] October 26, 2018 VANCOUVER, British Columbia \u2014 Vancouver based microbiome startup Derm-Biome Pharmaceuticals Inc. is excited to announce that it has contracted the Centre for Drug Research and Development (CDRD) to commence testing its patented compounds on various pathogens. Lead compound DB-207 shows significant potential in patients […]<\/p>","protected":false},"author":2,"featured_media":219,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent-news"],"yoast_head":"\nDerm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets. - Derm-Biome Pharmaceuticals Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets. - Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] October 26, 2018 VANCOUVER, British Columbia \u2014 Vancouver based microbiome startup Derm-Biome Pharmaceuticals Inc. is excited to announce that it has contracted the Centre for Drug Research and Development (CDRD) to commence testing its patented compounds on various pathogens. Lead compound DB-207 shows significant potential in patients […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/\" \/>\n<meta property=\"og:site_name\" content=\"Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-27T06:14:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-24T07:54:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"539\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Derm-Biome Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschrieben von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Derm-Biome Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/\"},\"author\":{\"name\":\"Derm-Biome Admin\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\"},\"headline\":\"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets.\",\"datePublished\":\"2018-10-27T06:14:59+00:00\",\"dateModified\":\"2019-01-24T07:54:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets. - Derm-Biome Pharmaceuticals Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg\",\"datePublished\":\"2018-10-27T06:14:59+00:00\",\"dateModified\":\"2019-01-24T07:54:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg\",\"width\":1000,\"height\":539},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/derm-biomepharmaceuticals.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc.\",\"description\":\"Startup Biopharmaceutical Company\",\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\",\"name\":\"Derm-Biome Pharmaceuticals\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"width\":450,\"height\":200,\"caption\":\"Derm-Biome Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\",\"name\":\"Derm-Biome Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"caption\":\"Derm-Biome Admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets. - Derm-Biome Pharmaceuticals Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/","og_locale":"de_DE","og_type":"article","og_title":"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets. - Derm-Biome Pharmaceuticals Inc.","og_description":"[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] October 26, 2018 VANCOUVER, British Columbia \u2014 Vancouver based microbiome startup Derm-Biome Pharmaceuticals Inc. is excited to announce that it has contracted the Centre for Drug Research and Development (CDRD) to commence testing its patented compounds on various pathogens. Lead compound DB-207 shows significant potential in patients […]","og_url":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/","og_site_name":"Derm-Biome Pharmaceuticals Inc.","article_published_time":"2018-10-27T06:14:59+00:00","article_modified_time":"2019-01-24T07:54:24+00:00","og_image":[{"width":1000,"height":539,"url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg","type":"image\/jpeg"}],"author":"Derm-Biome Admin","twitter_card":"summary_large_image","twitter_misc":{"Geschrieben von":"Derm-Biome Admin","Gesch\u00e4tzte Lesezeit":"1 Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#article","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/"},"author":{"name":"Derm-Biome Admin","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d"},"headline":"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets.","datePublished":"2018-10-27T06:14:59+00:00","dateModified":"2019-01-24T07:54:24+00:00","mainEntityOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg","articleSection":["Recent News"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/","url":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/","name":"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets. - Derm-Biome Pharmaceuticals Inc.","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg","datePublished":"2018-10-27T06:14:59+00:00","dateModified":"2019-01-24T07:54:24+00:00","breadcrumb":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#primaryimage","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2018\/10\/2018Oct-Announcement-cover.jpg","width":1000,"height":539},{"@type":"BreadcrumbList","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-commences-testing-its-proprietary-compounds-on-skin-microbiome-targets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/derm-biomepharmaceuticals.com\/"},{"@type":"ListItem","position":2,"name":"Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets."}]},{"@type":"WebSite","@id":"https:\/\/derm-biomepharmaceuticals.com\/#website","url":"https:\/\/derm-biomepharmaceuticals.com\/","name":"Derm-Biome Pharmaceuticals Inc.","description":"Startup Biopharmaceutical Company","publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization","name":"Derm-Biome Pharmaceuticals","url":"https:\/\/derm-biomepharmaceuticals.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","width":450,"height":200,"caption":"Derm-Biome Pharmaceuticals"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d","name":"Derm-Biome Admin","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","caption":"Derm-Biome Admin"}}]}},"_links":{"self":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/209"}],"collection":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/comments?post=209"}],"version-history":[{"count":8,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/209\/revisions"}],"predecessor-version":[{"id":226,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/209\/revisions\/226"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media\/219"}],"wp:attachment":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media?parent=209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/categories?post=209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/tags?post=209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}